The desire of the UK's Orchard Therapeutics to become a key player globally in the gene therapy space has received a major boost this morning (Dec. 20) with the completion of an oversubscribed $110m financing, backed by powerhouse healthcare investors.
"It is a serious fundraise," CEO Mark Rothera told Scrip in an interview, and the Series B round, co-led by Baillie Gifford and ORI Capital, has attracted significant new investments from Singapore's Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital and 4BIO Capital, as well as existing investors F-Prime Capital and UCL Technology Fund
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?